Additive effect of cysteinyl leukotriene or thromboxane modifiers to inhaled corticosteroids in asthmatic patients

Allergology International

Volumn 53, Issue 3, 2004, Pages 211-217

  Myou, Shigeharu ^a   Fujimura, Masaki ^a   Leff, Alan R ^b  

^a Graduate School of Medicine   (Japan)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Asthma; Corticosteroid; Cysteinyl leukotriene; Thromboxane

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; OZAGREL; PREDNISONE; SALMETEROL; SERATRODAST; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; ZAFIRLUKAST;

AIRWAY CONDUCTANCE; ASTHMA; BIOSYNTHESIS; CHRONIC INFLAMMATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; HUMAN; MAINTENANCE THERAPY; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

EID: 4944251138     PISSN: 13238930     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1592.2004.00336.x     Document Type: Review

References (48)

1. National Heart, Lung and Blood Institute. Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention. Bethesda: National Institutes of Health. 2002.
2. British Thoracic Society, Scottish Intercollegiate Guideline Network. British guidelines on the management of asthma. Thorax 2003; 58 (Suppl. 1): I-1-94.
3. Busse W, Raphael GD, Galant S et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial. J. Allergy Clin. Immunol. 2001; 107: 461-8.
4. Bleecker ER, Welch MJ, Weinstein SF et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J. Allergy Clin. Immunol. 2000; 105: 1123-9.
5. Demoly P, Jaffuel D, Mathieu M et al. Glucocorticoid insensitive asthma: A one year clinical follow up pilot study. Thorax 1998; 53: 1063-5.
6. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219-24.
7. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N. Engl. J. Med. 1997; 337: 1412-18.
8. Lipworth BJ. Leukotriene-receptor antagonists. Lancet 1999; 353: 57-62.
9. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. 1999; 340: 197-206.
10. Gryglewski RJ, Panczenko B, Korbut R, Grodzinska L, Ocetkiewicz A. Corticosteroids inhibit prostaglandin release from perfused mesenteric blood vessels of rabbit and from perfused lungs of sensitized guinea pig. Prostaglandins 1975; 10: 343-55.
11. Hong SL, Levine L. Inhibition of arachidonic acid release from cells as the biochemical action of anti-inflammatory corticosteroids. Proc. Natl Acad. Sci. USA 1976; 73: 1730-4.
12. Balter MS, Eschenbacher WL, Peters-Golden M. Arachidonic acid metabolism in cultured alveolar macrophages from normal, atopic, and asthmatic subjects. Am. Rev. Respir. Dis. 1988; 138: 1134-42.
13. Pavord ID, Ward R, Woltmann G, Wardlaw AJ, Sheller JR, Dworski R. Induced sputum echinoid concentrations in asthma. Am. J. Respir. Crit. Care Med. 1999; 160: 1905-9.
14. 4 excretion. Am. Rev. Respir. Dis. 1993; 147: 1472-6.
15. Dworski R, Fitzgerald GA, Gates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am. J. Respir. Crit. Care Med. 1994; 149: 953-9.
16. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am. J. Respir. Crit Care Med. 1997; 156: 737-43.
17. Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanovic R The relationship between airways inflammation and asthma severity. Am. J. Respir. Crit. Care Med. 2000; 161: 9-16.
18. National Heart, Lung, and Blood Institute. Highlights of the Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 97-4051A. Bethesda: National Institutes of Health (National Heart, Lung, and Blood Institute). 1997.
19. Laviolette M, Malmstrom K, Lu S et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am. J. Respir. Crit. Care Med. 1999; 160: 1862-8.
20. Christian Virchow J, Prasse A, Naya I, Summerton L, Harris A. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 2000; 162: 578-85.
21. Price DB, Hernandez D, Magyar P et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58: 211-16.
22. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am. J. Med. 1995; 98: 196-208.
23. Meeran K, Hattersley A, Burrin J, Shiner R, Ibbertson K. Oral and inhaled corticosteroids reduce bone formation as shown by plasma osteocalcin levels. Am. J. Respir. Crit. Care Med. 1995; 151: 333-6.
24. Nikolaizik WH, Marchant JL, Preece MA, Warner JO. Nocturnal cortisol secretion in healthy adults before and after inhalation of budesonide. Am. J. Respir. Crit. Care Med. 1996; 153: 97-101.
25. Ip M, Lam K, Yom L, Kung A, Ng M. Decreased bone mineral density in premenopausol asthma patients receiving long-term inhaled steroids. Chest 1994; 105: 1722-7.
26. Tohda Y, Fujimuro M, Taniguchi H et al. Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients. Clin. Exp. Allergy 2002; 32: 1180-6.
27. Lofdahl CG, Reiss TF, Leff JA et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319: 87-90.
28. Tamaoki J, Kondo M, Sakai N et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am. J. Respir. Crit. Care Med. 1997; 155: 1235-40.
29. Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am. J. Respir. Crit. Care Med. 2003; 167: 1232-8.
30. Barnes PJ. Clinical outcome of adding long-acting beta-agonists to inhaled corticosteroids. Respir. Med. 2001; 95: S12-16.
31. Jarvis B, Markham A. Montelukast: A review of its therapeutic potential in persistent asthma. Drugs 2000; 59: 891-928.
32. Bjermer L, Bisgaard H, Bousquet J et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: One year, double blind, randomised, comparative trial. BMJ 2003; 327: 891-6.
33. Szczeklik A, Stevenson DD. Aspirin-induced asthma: Advances in pathogenesis and management. J. Allergy Clin. Immunol. 1999; 104: 5-13.
34. 4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am. Rev. Respir. Dis. 1991; 143: 1025-9.
35. Antczak A, Montuschi P, Kharitonov S, Gorski P, Barnes PJ. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am. J. Respir. Crit. Care Med. 2002; 166: 301-6.
36. 4, and histamine in asthmatics. Am. Rev. Respir. Dis. 1992; 146: 96-103.
37. Dahlen B, Kumlin M, Margolskee DJ et al. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur. Respir. J. 1993; 6: 1018-26.
38. Dahlen SE, Malmstrom K, Nizankowska E et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene ontogonist: A randomized, double-blind, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2002; 165: 9-14.
39. Jones GL, Saroea HG, Watson RM, O'Byrne PM. Effect of an inhaled thromboxane mimetic (U46619) on airway function in humon subjects. Am. Rev. Respir. Dis. 1992; 145: 1270-4.
40. Kitamura S, Ishihara Y, Takaku F. Effect of thromboxane synthetase inhibitors (OKY-046, OKY-1580) on the action of bronchoactive agents in guinea pig tracheal strips and on arachidonate metabolism in guinea pig lung lobes. Prostaglandins Leukot. Med. 1984; 14: 341-50.
41. Barnes PJ. New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. J. Allergy Clin. Immunol. 1989; 83: 1013-26.
42. Djukanovic R, Roche WR, Wilson JW et al. Mucosal inflammation in asthma. Am. Rev. Respir. Dis. 1990; 142: 434-57.
43. Fujimura M, Sasaki F, Nakatsumi Y et al. Effects of a thromboxane synthetase inhibitor (OKY-046) and a lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects. Thorax 1986; 41: 955-9.
44. 2 receptor antagonist (AA-2414) on bronchial hyperresponsiveness to methacholine in subjects with asthma. J. Allergy Clin. Immunol. 1991; 87: 23-7.
45. Fujimura M, Nakatsumi Y, Nishi K, Ogawa H, Kasahara K, Matsuda T. Effect of a thromboxane synthetase inhibitor, ozagrel hydrochloride, on peak expiratory flow in stable asthmatics treated with beclomethasone dipropionate. Allergol. Int. 1997; 46: 25-8.
46. Fukuoka T, Miyake S, Umino T, Inase N, Tojo N, Yoshizawa Y. The effect of seratrodast on eosinophil cationic protein and symptoms in asthmatics. J. Asthma 2003; 40: 57-64.
47. 2 receptor antagonist in asthmatic patients? Respir. Med. 1999; 93: 891-7.
48. 2receptor antagonist, on airway inflammation in subjects with asthma. J. Allergy Clin. Immunol. 1999; 103: 1054-61.